Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Vopr Virusol ; 69(2): 119-126, 2024 May 06.
Article de Russe | MEDLINE | ID: mdl-38843018

RÉSUMÉ

INTRODUCTION: When a new disease occurs, one of the most affordable remedies is drugs containing specific antibodies to this infectious agent. The use of such drugs is aimed at reducing the amount of the pathogen in the macroorganism and the associated reduction in the severity of the symptoms of the disease or recovery. The purpose of this review is to analyze the experience of using immunoglobulins and monoclonal antibodies in the treatment of COVID-19 patients during the pandemic. RESULTS AND CONCLUSION: The two main groups of medical protective agents that block the penetration of the SARS-CoV-2 virus into permissive cells are drugs obtained from blood plasma of convalescents (immunoglobulin) and human monoclonal antibodies. The first group of drugs in the treatment of COVID-19 includes blood plasma of convalescents, which can be successfully used for emergency prevention. The main disadvantage of using blood plasma convalescents is the difficulty of standardization due to the different content of specific antibodies in donors. Another disadvantage is the undesirable side effects in recipients that occur after plasma administration. An alternative approach to COVID-19 therapy is the use of humanized and genetically engineered human monoclonal antibodies against certain epitopes of the SARS-CoV-2 virus. For example, monoclonal antibodies against receptor-binding domain of the S-protein, which prevents the virus from entering permissive cells and interrupts the development of infection. The advantages of these drugs are their safety, high specific activity, and the possibility of standardization. However, the complexity of their production and high cost make them inaccessible for mass use in practical medicine.


Sujet(s)
Anticorps monoclonaux , COVID-19 , SARS-CoV-2 , Humains , SARS-CoV-2/immunologie , SARS-CoV-2/effets des médicaments et des substances chimiques , COVID-19/immunologie , COVID-19/thérapie , Anticorps monoclonaux/usage thérapeutique , Anticorps monoclonaux/immunologie , Anticorps antiviraux/immunologie , Anticorps antiviraux/usage thérapeutique , Immunoglobulines/usage thérapeutique , Immunoglobulines/immunologie , Traitements médicamenteux de la COVID-19 , Sérothérapie COVID-19 , Immunisation passive , Pandémies , Anticorps monoclonaux humanisés/usage thérapeutique , Anticorps monoclonaux humanisés/immunologie , Antiviraux/usage thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE